PsA Cycling or Switching MOAs Dr. Tate ( @uptoTate) interviews Dr. Alexis Ogdie ( @AlexisO) at #ACR22 on Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA https://t.co/S83Wbpbd4V https://t.co/B1gTmMAzc1